Drug­mak­er fined by Span­ish reg­u­la­tors $10M for 'ex­ces­sive price' of rare dis­ease drug

A com­pa­ny that has been un­der the mi­cro­scope for drug pric­ing be­fore has found it­self fined by Span­ish reg­u­la­tors.

Lea­di­ant Bio­sciences has been fined €10.3 mil­lion ($10.6 mil­lion) by the Span­ish reg­u­la­tors Comisión Na­cional de Los Mer­ca­dos y la Com­pe­ten­cia (CN­MC), af­ter a mas­sive price hike of its chen­odeoxy­cholic acid (CD­CA) com­pound, which is used to treat the rare dis­ease cere­bro­tendi­nous xan­thomato­sis (CTX).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.